Fusion Pharmaceuticals (FUSN) Stock Forecast, Price Target & Predictions
FUSN Stock Forecast
Fusion Pharmaceuticals stock forecast is as follows: an average price target of $15.25 (represents a -29.23% downside from FUSN’s last price of $21.55) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.
FUSN Price Target
FUSN Analyst Ratings
Hold
Fusion Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Mar 19, 2024 | Matthew Harrison | Morgan Stanley | $21.00 | $21.18 | -0.85% | -2.55% |
Mar 19, 2024 | Suji Jeong | Jefferies | $21.00 | $21.18 | -0.85% | -2.55% |
Sep 29, 2023 | Jeff Jones | Oppenheimer | $13.00 | $2.60 | 400.00% | -39.68% |
Nov 30, 2022 | - | Leerink Partners | $6.00 | $2.16 | 177.78% | -72.16% |
10
Fusion Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $21.00 |
Last Closing Price | $21.55 | $21.55 | $21.55 |
Upside/Downside | -100.00% | -100.00% | -2.55% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Apr 16, 2024 | Cowen & Co. | - | Hold | Downgrade |
Mar 20, 2024 | Wedbush | Sector Perform | Sector Perform | Hold |
Mar 19, 2024 | Leerink Partners | - | Market Perform | Downgrade |
Mar 04, 2024 | Wedbush | Strong Buy | Strong Buy | Hold |
Jan 26, 2024 | Wedbush | Strong Buy | Strong Buy | Hold |
Dec 27, 2023 | Raymond James | Outperform | Strong Buy | Upgrade |
Dec 27, 2023 | RBC Capital | Strong Buy | Strong Buy | Hold |
Jun 23, 2023 | B. Riley Securities | - | Neutral | Initialise |
Jun 23, 2023 | Compass Point | - | Sell | Initialise |
Jun 23, 2023 | Piper Sandler | - | Neutral | Initialise |
10
Fusion Pharmaceuticals Financial Forecast
Fusion Pharmaceuticals Revenue Forecast
Quarter
Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $28.00K | $140.00K | - | - | $585.00K | - | - |
Avg Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.50K | $412.40K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
High Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.75K | $793.08K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
Low Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.25K | $31.72K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 8.24% | - | - | 0.41% | - | - |
Forecast
Fusion Pharmaceuticals EBITDA Forecast
Quarter
Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-27.91M | - | - | $-23.08M | $-23.79M | - | - | $-20.32M | - | - |
Avg Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.70K | $-82.48K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-20.50M | $-52.10K | $-666.67K |
High Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.65K | $-6.34K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-16.40M | $-52.10K | $-666.67K |
Low Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.75K | $-158.62K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-24.60M | $-52.10K | $-666.67K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 338.44% | - | - | 13.46% | 6998.53% | - | - | 0.99% | - | - |
Forecast
Fusion Pharmaceuticals Net Income Forecast
Quarter
Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-28.18M | - | - | $-24.29M | $-24.62M | - | - | $-19.91M | - | - |
Avg Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-29.53M | $-31.11M | $-28.40M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-20.74M | $-48.42M | $-15.50M |
High Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-22.35M | $-31.11M | $-22.56M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-16.59M | $-48.42M | $-15.50M |
Low Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-35.12M | $-31.11M | $-35.09M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-24.89M | $-48.42M | $-15.50M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | - | - | 0.94% | 0.54% | - | - | 0.96% | - | - |
Forecast
Fusion Pharmaceuticals SG&A Forecast
Quarter
Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.63M | - | - | $9.01M | $6.95M | - | - | $8.45M | - | - |
Avg Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.92M | $4.69M | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
High Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.92M | $9.02M | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
Low Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.91M | $360.68K | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.63% | - | - | 0.09% | 35.96% | - | - | 0.52% | - | - |
Forecast
Fusion Pharmaceuticals EPS Forecast
Quarter
Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.39 | - | - | $-0.45 | $-0.55 | - | - | $-0.46 | - | $-0.32 |
Avg Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.35 | $-0.37 | $-0.34 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
High Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.27 | $-0.37 | $-0.27 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
Low Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.42 | $-0.37 | $-0.42 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | - | - | 1.45% | 1.00% | - | - | 1.04% | - | 1.73% |
Forecast
Fusion Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
RAPT | RAPT Therapeutics | $1.05 | $30.71 | 2824.76% | Hold |
PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
SPRO | Spero Therapeutics | $1.19 | $10.00 | 740.34% | Buy |
CHRS | Coherus BioSciences | $1.10 | $9.00 | 718.18% | Hold |
OLMA | Olema Pharmaceuticals | $7.87 | $28.50 | 262.13% | Buy |
BCAB | BioAtla | $1.39 | $5.00 | 259.71% | Buy |
FENC | Fennec Pharmaceuticals | $4.72 | $15.75 | 233.69% | Buy |
BCYC | Bicycle Therapeutics | $20.26 | $54.40 | 168.51% | Buy |
RLMD | Relmada Therapeutics | $2.75 | $5.67 | 106.18% | Buy |
KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
NAMS | NewAmsterdam Pharma Company | $20.12 | $36.50 | 81.41% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
HRMY | Harmony Biosciences | $33.23 | $48.86 | 47.04% | Buy |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
JANX | Janux Therapeutics | $46.50 | $61.20 | 31.61% | Buy |
IKNA | Ikena Oncology | $1.73 | $1.33 | -23.12% | Buy |
FUSN | Fusion Pharmaceuticals | $21.55 | $15.25 | -29.23% | Hold |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |